Deans' stroke musings: Does Brain Reserve Attenuate the Effects of Alzheimer Disease Pathology?

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, June 4, 2026

Does Brain Reserve Attenuate the Effects of Alzheimer Disease Pathology?

Have your competent? doctor give you EXACT PROTOCOLS TO BUILD BRAIN RESERVE and thus prevent dementia post stroke! Oh, can't or won't do that? INCOMPETENCE PERSONIFIED! Fire them!

(My cognitive reserve was obviously high enough to withstand the stroke quite well. But NO one can tell me how or if I can build it up again to prevent dementia.)

Does Brain Reserve Attenuate the Effects of Alzheimer Disease Pathology?

Greater brain reserve and higher socioeconomic status were associated with reduced cognitive vulnerability to Alzheimer disease pathology among cognitively unimpaired older adults.

Greater cognitive and brain reserve may buffer the cognitive consequences of Alzheimer disease (AD) pathology, according to a study published in Neurology.

Researchers from AdventHealth Research Institute in the United States evaluated whether measures of cognitive and brain reserve modified the relationship between AD pathology and cognitive performance using baseline data from the Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE) study (ClinicalTrials.gov Identifier: NCT02875301).

Adults (N=621) aged 65 to 80 years who were cognitively unimpaired and physically inactive between 2017 and 2020 underwent cognitive assessment, magnetic resonance imaging (MRI), and plasma sampling for phosphorylated tau (p-tau) 217. A subset of participants (n=355) also underwent positron emission tomography (PET). The primary outcome was the effect of brain-predicted age difference (brain-PAD) and volumetric AD phenotype on cognitive performance. Objective socioeconomic status (SES) was calculated as a composite of annual family income, total savings, debt-adjusted savings, and duration of standard of living maintenance if current income was lost.

[W]e found some evidence that higher SES weakens the relationship between AD pathology and cognitive function, highlighting the need for further research in this area and to address socioeconomic inequalities…

The study population was 71% women and 75% White, with a mean (SD) age of 69.9 (3.8) years. The participants had completed a mean (SD) of 16.3 (2.2) years of education, and mean (SD) objective SES was 0.0 (0.91). In addition, 27% were apolipoprotein E (APOE) ε4 carriers, mean (SD) Montreal Cognitive Assessment (MoCA) score was 25.8 (2.6), and mean (SD) p-tau217 level was 0.43 (0.28) pg/mL.

The cohort had a mean (SD) brain-PAD of -4.05 (6.7) years and a mean (SD) AD signature of 64,958.6 (5387.4) mm3.

The AD signature was negatively correlated with brain-PAD (r, -0.204; P ≤.001) and positively correlated with executive function/attentional control (r, 0.217; P ≤.001), working memory (r, 0.214; P ≤.001), processing speed (r, 0.197; P ≤.001), visuospatial function (r, 0.193; P ≤.001), and episodic memory (r, 0.132; P ≤.001).

Years of education (β range, 0.18-0.30; all P <.001) and objective SES (β range, 0.11-0.21; all P <.004) were significantly associated with cognitive performance across domains. However, years of education did not moderate the relationship between p-tau217 and cognitive outcomes.

Significant brain-PAD-by-p-tau217 interactions were observed for working memory (β, -0.10; P <.01), episodic memory (β, -0.09; P <.05), processing speed (β, -0.08; P <.05), and executive function/attentional control (β, -0.08; P <.05). When AD signature was included in the brain-PAD moderation analysis, brain-PAD continued to interact with p-tau217 levels for working memory (β, -0.10; P =.008), episodic memory (β, -0.08; P =.025), and executive function/attentional control (β, -0.07; P =.044).

Volumetric AD signature did not moderate the relationship between p-tau17 or PET centiloids and cognitive outcomes.

Study limitations include the cross-sectional design, lack of PET data from the full cohort, and limited generalizability because the population was relatively well educated and predominantly non-Hispanic White.

The study authors concluded, “These results suggest that greater brain reserve may help buffer the cognitive consequences of AD pathology.” They continued, “In addition, we found some evidence that higher SES weakens the relationship between AD pathology and cognitive function, highlighting the need for further research in this area and to address socioeconomic inequalities as contributors to improving brain health.”

Disclosures: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.